menu
    • menu
    [{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Dendritic Cell Vaccine","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diakonos Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Diakonos Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Diakonos Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Diakonos Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Restem Group Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Diakonos Oncology","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Restem Group Inc","highestDevelopmentStatusID":"8","companyTruncated":"Diakonos Oncology \/ Restem Group Inc"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Joseph Gunnar & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Private Placement","leadProduct":"Dubodencel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Diakonos Oncology","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Joseph Gunnar & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Diakonos Oncology \/ Joseph Gunnar & Co. LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by Diakonos Oncology

    Menu

    Diakonos Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dubodencel,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Joseph Gunnar & Co. LLC

                            Deal Size : $20.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program...

                            Details : The proceeds will accelerate Phase 2 glioblastoma trial for dubodencel, aka DOC1021, and support the expansion of its clinical portfolio to other indications, including refractory melanoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 30, 2025

                            Lead Product(s) : Dubodencel,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Joseph Gunnar & Co. LLC

                            Deal Size : $20.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

                            Details : DOC1021 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 03, 2025

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Restem Group Inc

                            Deal Size : $11.4 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Diakonos Closes $11.4M Seed Financing to Advance Dendritic Cell Vaccine DOC1021

                            Details : The financing aims to fund the company's lead product DOC1021 to initiate the mid-stage clinical trial studies to treat patients suffering from Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 26, 2024

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Restem Group Inc

                            Deal Size : $11.4 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dendritic Cell Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Diakonos Oncology Receives FDA Fast Track for Pancreatic Cancer Vaccine

                            Details : Company’s unique dendritic cell vaccine, which activate robust cytotoxic TH1 cell signaling pathways, received fast track designation for pancreatic ductal adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 15, 2024

                            Lead Product(s) : Dendritic Cell Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Diakonos Completes Recruitment for Phase 1 Glioblastoma Trial; Receives FDA Orphan Drug

                            Details : DOC1021 is a unique dendritic cell vaccine which is under phase 1 clinical development for the treatment of patients with Glioblastoma Multiforme (GBM).

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 02, 2024

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Diakonos Oncology

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

                            Details : DOC1021 Dendritic Cell Vaccine based Diakonos’ proprietary “double-loading” technique, which is investigated for the treatment of patients with glioblastoma multiforme.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : DOC1021

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth